Search research articles
Contact Us
Filters
Showing results (1-10 of 22) with videos related to
Page
of 3
Sort By:
Disease-A-Month : DM
|
August 31, 2010
Approach to anemia
Maen Hussein, Rami Y Haddad
Immunotherapy
|
February 6, 2026
Friendly fire? A case of inadvertent reactivation and progression of chronic lymphocytic leukemia following the treatment of cutaneous squamous cell carcinoma with Cemiplimab - case report
Adewale A Fawole, Maen Hussein, Muna A AlShawabkeh
Cancer Management and Research
|
August 19, 2021
Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies
Maen Hussein, Marina Maglakelidze, Donald A Richards, et al.
BMC Cancer
|
July 25, 2024
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study
Takaaki Tokito, Oleksii Kolesnik, Jens Sørensen, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 28, 2024
Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations
David S Hong, Federico Cappuzzo, Byoung Chul Cho, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 30, 2023
Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study
Myung-Ju Ahn, Igor Bondarenko, Ewa Kalinka, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 18, 2020
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
Robert Jotte, Federico Cappuzzo, Ihor Vynnychenko, et al.
The Lancet. Oncology
|
May 25, 2019
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West, Michael McCleod, Maen Hussein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 3, 2022
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study
Melissa L Johnson, Byoung Chul Cho, Alexander Luft, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 22, 2023
Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)
Edward B Garon, Byoung Chul Cho, Alexander Luft, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 22) with videos related to
Sort By:
Page
of 3
Disease-A-Month : DM
|
August 31, 2010
Approach to anemia
Maen Hussein, Rami Y Haddad
Immunotherapy
|
February 6, 2026
Friendly fire? A case of inadvertent reactivation and progression of chronic lymphocytic leukemia following the treatment of cutaneous squamous cell carcinoma with Cemiplimab - case report
Adewale A Fawole, Maen Hussein, Muna A AlShawabkeh
Cancer Management and Research
|
August 19, 2021
Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies
Maen Hussein, Marina Maglakelidze, Donald A Richards, et al.
BMC Cancer
|
July 25, 2024
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study
Takaaki Tokito, Oleksii Kolesnik, Jens Sørensen, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 28, 2024
Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations
David S Hong, Federico Cappuzzo, Byoung Chul Cho, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 30, 2023
Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study
Myung-Ju Ahn, Igor Bondarenko, Ewa Kalinka, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 18, 2020
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
Robert Jotte, Federico Cappuzzo, Ihor Vynnychenko, et al.
The Lancet. Oncology
|
May 25, 2019
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West, Michael McCleod, Maen Hussein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 3, 2022
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study
Melissa L Johnson, Byoung Chul Cho, Alexander Luft, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 22, 2023
Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)
Edward B Garon, Byoung Chul Cho, Alexander Luft, et al.
Page
of 3